Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Sanofi Aventis Pakistan Ltd (SAPL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
850.00 +0.00    +0.00%
00:55:30 - Closed. Currency in PKR ( Disclaimer )
Type:  Equity
Market:  Pakistan
ISIN:  PK0021801011 
S/N:  SAPL
  • Volume: 50
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 850.00 - 850.00
Sanofi Aventis Pakistan 850.00 +0.00 +0.00%
IndustryPharmaceuticals
SectorHealthcare
Employees

869

Equity Type

ORD

sanofi-aventis Pakistan Limited manufactures and sells pharmaceuticals, consumer healthcare products, and vaccines primarily in Pakistan, Afghanistan, and internationally. It offers products for diabetes that include oral products under the Amaryl, Daonil, and Neodipar names, as well as insulins under the Toujeo, Lantus, SoloSTAR, and Apidra names; oncology products under the Thyrogen, Jevtana, Taxotere, Eloxatin, and Fludara names; nephrology products under the Renvela name; organ transplantation products under the Thymoglobulin name; urology products under the Xatral name; pain management products under the No-Spa and Muscoril; and antiemetic products under the Stemetil name. The company also provides products for allergy management under the Telfast, Telfast-D, Avil, Nasacort, Phenergan, and Tixylix names; products for sleep disorders under the Stilnox name; products for emergency care under the Haemaccel name; and cardiology products under the Plavix, CoPlavix, Aprovel, CoAprovel, Cordarone, Clexane, Tritace, CoTritace, Winstor, and Lasix/Lasoride names. In addition, it offers antibiotic products under the Flagyl, Tarivid, Claforan, Aventriax, Orelox, Tavanic, Targocid, and Rulid names; anti-diarrheals under the Secnidal Forte and Enterogermina names; products for epilepsy under the Frisium name; products for rare disorders under the Myozyme and Aubagio names; consumer healthcare products under the Selsun Blue name; and vaccines under the Menactra, Verorab, Typhim, Vaxigrip, VaxigripTetra, Stamaril, and Hexaxim names. The company was formerly known as Aventis Limited and changed its name to sanofi-aventis Pakistan Limited in September 2005. sanofi-aventis Pakistan Limited was incorporated in 1967 and is headquartered in Karachi, Pakistan. sanofi-aventis Pakistan Limited is a subsidiary of Sanofi Foreign Participations B.V.

Contact Information

Top Executives

Name Age Since Title
Laila Khan - - Head of External Affairs
Yasser Pirmuhammad - 2016 CFO & Executive Director
Syed Muhammad Ali Hasani - - Director of Industrial Affairs
Asim Jamal - 2015 CEO & Executive Director
Syed Babar Ali - 1977 Non-Executive Chairman
Hermes Martet - 2020 Non-Executive Director
Rehmatullah Khan Wazir - 2020 Independent Director
Syed Hyder Ali - 1987 Non-Executive Director
Naira Adamyan - 2019 Non Executive Director
Imtiaz Ahmed Husain Laliwala - 2017 Independent Director
Shahid Zaki - 2020 Independent Director
Marc-Antoine Lucchini 56 2020 Non-Executive Director
Arshad Ali Gohar - 2011 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SAPL Comments

Write your thoughts about Sanofi Aventis Pakistan Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email